The Ipsen Investment Case

FY 2021: Neuroscience sales highlights Dysport €m sales +26.3% Dysport® Clostridium botulinum Type A Toxin Aesthetics Strong performance across all key Ipsen and Galderma markets Full recovery from the pandemic Market growth driven by favorable consumer dynamics 353 2020 435 2021 Therapeutics Strong performance supported by solid market growth Numbers of injections recovering towards pre-pandemic level Ipsen's focus on spasticity indications and the penetration of neurotoxins to address the significant unmet medical need IPSEN Innovation for patient care All growth rates at constant exchange rates. Absolute values are shown at actual exchange rates. 24 24

View entire presentation